Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma

Goran Pancevski; Senada Pepic; Sanela Idoska; Gligor Tofoski; Suzana Nikolovska

doi:10.3889/oamjms.2018.133

Authors

Goran Pancevski University Clinic for Maxillofacial Surgery, Ss Cyril and Methodius University of Skopje, Skopje
Senada Pepic University Clinic of Dermatology, Ss Cyril and Methodius University of Skopje, Skopje
Sanela Idoska University Clinic for Maxillofacial Surgery, Ss Cyril and Methodius University of Skopje, Skopje
Gligor Tofoski University Clinic of Gynecology and Obstetrics, Ss Cyril and Methodius University of Skopje, Skopje
Suzana Nikolovska University Clinic of Dermatology, Ss Cyril and Methodius University of Skopje, Skopje

DOI:

https://doi.org/10.3889/oamjms.2018.133

Keywords:

Solitary keratoacanthoma, treatment, Imiquimode

Abstract

BACKGROUND: Keratoacanthoma (KA) is a rapidly growing epithelial tumour with histopathologic and clinical features similar to squamous cell carcinoma (SCC) and a certain tendency toward spontaneous regression.

CASE PRESENTATION: This article presents a unique and rare case of keratoacanthoma arising from the upper lip of a young male patient. These two features are in contrast to most of the reported cases in elder male individuals and on the lower lip. Relevant management protocol of the case has also been discussed.

CONCLUSION: The article emphasises the significance of discerning such lesions from squamous cell carcinoma thus carrying diagnostic and therapeutic implications. However, in case of the dilemma it is prudent to assume that the lesion is SCC unless proved otherwise clinically and histologically.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Janik JP, Bang RH. Traumatic Keratoacanthoma Arising in a 15-Year-Old-Boy Following a Motor Vehicle Accident. Pediatric Dermatology. 2006; 23: 448-450. https://doi.org/10.1111/j.1525-1470.2006.00280.x PMid:17014639

Kamath P, Pereira T, Chande M, Shetty S. Keratoacanthoma of the lip: A case report with emphasis on histogenesis. J Oral Maxillofac Pathol. 2017; 21(1):115-118. https://doi.org/10.4103/jomfp.JOMFP_217_16 PMid:28479697 PMCid:PMC5406790

Azaz B, Lustmann J. Keratoacanthoma of the lower lip: Review of the literature and report of a case. Oral Surgery, Oral Medicine, Oral Pathology. 1974; 38(6):918-27. https://doi.org/10.1016/0030-4220(74)90345-4

Patil PB, Rathor V, Venkatraman S, SaxenaS, Kamarthi N. Solitary keratoacanthoma involving upper lip: A diagnostic dilemma â€“ Case report and a brief review. J Clin Exp Dent. 2010; 2(1):e33-36. https://doi.org/10.4317/jced.2.e34

Hardman FG. Keratoacanthoma on the lips. Br J Oral Surg. 1971; 9: 46-53. https://doi.org/10.1016/S0007-117X(71)80008-2

Mattoo KA, Singh M, Singh V. Muco-cutaneous Keratoacanthoma Involving Maxillary Lip. Oral Surgery, Oral Medicine, Oral Radiology. 2014: 2(2): 21-22.

de Visscher JG, van der Wal KG, Blanken R, Willemse F. Treatmentof giant keratoacanthoma of the skin of the lower lip with intralesional methotrexate: a case report. J Oral Maxillofac Surg. 2002; 60:93-5. https://doi.org/10.1053/joms.2002.29083 PMid:11757016

Hye Chan Jeon, M.D., Mira Choi, M.D., Seung Hwan Paik, M.D., Chang Ho Ahn, M.D., Hyun Sun Park, M.D., and Kwang Hyun Cho, M.D. Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous ReportAnn Dermatol. 2011; 23(3): 357â€“361.

Nima P Patel, MD and A Lawrence Cervino, MD Treatment of keratoacanthoma: Is intralesional methotrexate an option? Can J Plast Surg. 2011; 19(2): e15â€“e18. https://doi.org/10.1177/229255031101900209

Sanders S, Busam KJ, Halpern AC, Nehal KS. Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy. Dermatol Surg. 2002; 28(10):954-8. https://doi.org/10.1097/00042728-200210000-00013

Yuge S, Godoy DA, Melo MC, Sousa DS, Soares CT. Keratoacanthoma centrifugum marginatum: response to topical 5-fluorouracil. J Am Acad Dermatol. 2006; 54(5 Suppl):S218â€“S219. https://doi.org/10.1016/j.jaad.2005.07.023 PMid:16631944

Rossi AM, Park B, Qi B, Lee EH, Busam KJ, Nehal KS. Solitary Large Keratoacanthomas of the Head and Neck: An Observational Study. Dermatol Surg. 2017; 43(6):810-816. https://doi.org/10.1097/DSS.0000000000001080 PMid:28296794

Griffiths RW. Keratoacanthoma observed. Br J Plast Surg. 2004; 57(6):485-501. https://doi.org/10.1016/j.bjps.2004.05.007 PMid:15308394

Ganjian S, Ourian AJ, Shamtoub G, Wu JJ, Murase JE. Off-label indications for imiquimod. Dermatology online journal. 2009; 15(5). PMid:19624982

Na Young Ko, M.D., Jun Ha Park, M.D., Sang Wook Son, M.D. and Il Hwan Kim, M.D. Treatment of Keratoacanthoma with 5% Imiquimod Cream Ann Dermatol. 2006; 18(1):14-17. https://doi.org/10.5021/ad.2006.18.1.14

Di Lernia V, Ricci C, Albertini G. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream. J Eur Acad Dermatol Venereol. 2004; 18:626â€“629. https://doi.org/10.1111/j.1468-3083.2004.01025.x PMid:15324413

Tran DC, Li S, Henry S, Wood DJ, Chang AL. An 18â€year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic centre. British Journal of Dermatology. 2017; 177(6):1749-51. https://doi.org/10.1111/bjd.15225 PMid:27943239 PMCid:PMC5813161